Status:
COMPLETED
Ocrelizumab Effects on the Metabolome in MS
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-75 years
Brief Summary
In this observational study, the investigators aim to recruit 50 patients over an 10-12 month period. The investigators will recruit patients with relapsing-remitting MS (based on 2017 McDonald Criter...
Eligibility Criteria
Inclusion
- Between 18-75 years of age
- Diagnosis of relapsing remitting multiple sclerosis (RRMS) based on 2017 McDonald Criteria
- Initiating treatment with Ocrelizumab based on decision of the treating physician
- Able to return for visits every 6 months to Johns Hopkins MS Center
Exclusion
- Presence of additional neuroinflammatory or neurodegenerative disorder
- Steroids within the past 30 days
- Other significant metabolic comorbidity - eg: uncontrolled hypothyroidism or diabetes
- Likely to switch therapy in the following year
- Previous treatment with rituximab or other chemotherapy agents
Key Trial Info
Start Date :
June 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03873389
Start Date
June 12 2019
End Date
December 5 2023
Last Update
December 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins University
Baltimore, Maryland, United States, 21287